ASH 2024 Highlights: GMMG-HD7 Study
Panelists discuss how recent findings from the GMMG-HD7 trial comparing isatuximab-RVd vs RVd have shaped treatment decision-making in patients with multiple myeloma by providing comparative efficacy and safety data between the 2 regimens.
EP: 1.Expert Insights: Evolving Treatment Landscape in NDMM
EP: 2.Key Highlights From the PERSEUS and CASSIOPEIA Studies
EP: 3.ASH 2024 Updates —AURIGA: Daratumumab Plus Lenalidomide in Maintenance Post Transplant
EP: 4.Anti-CD38 Quadruplet Induction Regimens in TE NDMM: New Standard of Care
EP: 5.Clinical Perspectives: Selecting Between Daratumumab- and Isatuximab-Containing Quadruplet Induction Regimens
EP: 6.ASH 2024 Highlights: GMMG-HD7 Study
EP: 7.Where Are We Going? Future Perspectives on Navigating the Treatment Paradigm in Transplant-Eligible NDMM
EP: 8.Key Highlights: CEPHEUS Trial SubQ Dara-VRd vs VRd in Transplant-Eligible or Transplant-Deferred NDMM
EP: 9.Transplant-Ineligible NDMM: When to Use a Quadruplet Regimen
EP: 10.Expert Perspectives: Navigating Between CEPHEUS and IMROZ Studies
EP: 11.Challenges in Treating Frail Patients With NDMM: In the Real-World Practice: Potential Steroid-Free Regimens
EP: 12.Future Perspectives: What’s Next in NDMM?
EP: 13.Assessing CD38 Monoclonal Antibody-Based Regimens in NDMM
Video content above is prompted by the following:
- How have the latest data informed your treatment decision?
- GMMG-HD7, Isa-RVd vs RVd
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
